BPC-157 KPV is a prescription therapy used for gut and recovery support.

Patients seeking support for gut and recovery support may qualify after evaluation by a licensed provider.

Yes. BPC-157 / KPV is a compounded peptide capsule that requires a valid prescription from a licensed provider. A telehealth consultation and medical intake are required before dispensing to ensure this formulation is appropriate for your health history, goals, and current medications.

BPC-157 / KPV is generally well-tolerated at therapeutic oral doses. Mild GI symptoms including transient nausea, bloating, or loose stool have been reported during initial dosing, which typically resolves as the body adjusts. Some patients experience mild fatigue or changes in appetite during the first week of use. As with any compounded peptide therapy, individual responses vary. Report any unusual or persistent symptoms to your provider.

BPC-157 / KPV is not appropriate for patients who are pregnant or breastfeeding, as safety data in these populations is insufficient. Patients with a history of malignancy should not use BPC-157 without thorough oncological and provider evaluation, as BPC-157's angiogenic and tissue-proliferative properties carry theoretical risk in cancer populations. Patients with a history of melanoma or hormone-sensitive cancers should also disclose this before starting given KPV's melanocortin receptor activity. This formulation is not indicated for patients under 18. Disclose your full medical history and current medications before starting treatment.

Formal drug interaction studies for this combination have not been conducted. BPC-157 influences nitric oxide signaling and dopamine/serotonin pathways. Patients on antidepressants, antihypertensives, or medications affecting NO signaling should disclose concomitant use. KPV modulates melanocortin receptors and suppresses NF-κB — patients on immunosuppressive medications, corticosteroids, or biologic agents for autoimmune conditions should discuss additive anti-inflammatory effects with their provider. Always provide a complete medication list before beginning treatment.

Patients with a history of any malignancy should not use this combination without thorough oncological and provider evaluation due to BPC-157's angiogenic properties. Those with IBD, Crohn's disease, ulcerative colitis, or leaky gut syndrome are among the strongest candidates for this formulation and may benefit significantly under provider supervision. Patients with active autoimmune conditions on immunomodulatory therapy require careful review before adding KPV. Those with significant hepatic or renal impairment require individualized dosing review. Your provider requires a complete medical history before prescribing.